Article

Glaucoma 360: Getting updated with Glauconix Biosciences

 

Glauconix Biosciences' Kimberly Southern (CEO) and Karen Torrejon, PhD (CSO) sit down with Ophthalmology Times'® Sheryl Stevenson to discuss the company's role in using innovative platform technology to reduce the cost of ophthalmic drug development as well as what models are in their 2020 pipeline for the glaucoma and other eye-related diseases space, during this year's Glaucoma 360 annual meeting in San Francisco, California.

See more Glaucoma 360 content here. 

 

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Dr. Inder Paul Singh's Insights: Improving Glaucoma Outcomes with Early Intervention and Reduced Medication
© 2024 MJH Life Sciences

All rights reserved.